Recent Quotes (30 days)

You have no recent quotes
chg | %

Exactech, Inc.  

(Public, NASDAQ:EXAC)   Watch this stock  
Find more results for EXAC
-0.15 (-0.30%)
After Hours: 49.85 0.00 (0.00%)
Jan. 22, 4:40p.m. EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 49.70 - 50.00
52 week 23.30 - 50.95
Open 49.95
Vol / Avg. 0.00/157,933.00
Mkt cap 716.15M
P/E 3,591.50
Div/yield     -
EPS 0.01
Shares 14.37M
Beta 1.02
Inst. own 62%
Feb. 19, 2018
Q4 2017 Exactech Inc Earnings Release (Estimated) - 12:00a.m. EST - Add to calendar
Feb. 13, 2018
Exactech Inc Extraordinary Shareholders Meeting - 9:00a.m. EST - Add to calendar
Oct. 30, 2017
Q3 2017 Exactech Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep. '17) 2016
Net profit margin 4.72% 0.08%
Operating margin 6.40% 2.96%
EBITD margin - 16.51%
Return on average assets 3.82% 0.08%
Return on average equity 4.62% 0.07%
Employees 733 -
CDP Score - -


2320 NW 66th Ct
GAINESVILLE, FL 32653-1630
United States - Map
+1-352-3771140 (Phone)
+1-352-3782617 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Exactech, Inc. develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company's segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines. The Company distributes joint replacement systems, including knee, hip, spine and extremity implant systems, and biologic products and services and bone cement materials used in orthopedic surgery and dental procedures. The Exactech Knee System provides solutions for partial, primary and revision total knee arthroplasty. Its hip solutions address the continuum of hip arthroplasty. It manufactures and distributes various products and services designed for the healing and regeneration of bone and soft tissue, including products, which contain human allograft.

Officers and directors

R. William Petty M.D. Executive Chairman of the Board
Age: 74
Bio & Compensation  - Reuters
David W. Petty Chief Executive Officer, President and Director
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Joel C. Phillips CPA Chief Financial Officer, Executive Vice President, Treasurer
Age: 49
Bio & Compensation  - Reuters
Bruce E. Thompson Senior Vice President , General manager- Biologics and Spine Division
Age: 59
Bio & Compensation  - Reuters
Gary J. Miller Ph.D. Executive Vice President - Research and Development
Age: 69
Bio & Compensation  - Reuters
Donna M. Edwards Vice President, Legal and General Counsel
Age: 44
Bio & Compensation  - Reuters
Betty A. Petty Vice President - Administration, Corporate Secretary
Age: 74
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
James G. Binch Independent Director
Age: 69
Bio & Compensation  - Reuters
W. Andrew Krusen Jr. Independent Director
Age: 68
Bio & Compensation  - Reuters
William B. Locander Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters